The Quantellect read.As of Nov 19, 2026, 10 active firms cover Xenon Pharmaceuticals Inc: 9 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $46.00 to $90.00, a moderate spread. The average target of $67.40 sits 79% above the current $37.75. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.21 next quarter toward $-4.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy990%
Neutral110%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$67.40
+78.5% upside
Average target across 10 active firms as of Nov 19, 2026 vs $37.75 current
Highest Target$90.00
Average Target$67.40
Lowest Target$46.00
Detailed analyst forecasts for XENE
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 9 of 10 active firms rate XENE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
XENE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.21
Range $-1.30 – $-1.02 · 5 analysts · +3% YoY
Next period, 5 analysts expect Xenon Pharmaceuticals Inc to earn $-1.21 a share (range $-1.30 – $-1.02), versus $-1.17 a year earlier. Full-year consensus is $-4.56, growing to $-4.67 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $1.4M, rising to $30.0M next year.
Top analysts covering Xenon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XENE.
#1
Laura Chico
Wedbush · Rank #55
Buy
$55.00+45.7% to target
Overall win rate
46%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #84
Buy
$90.00+138.4% to target
Overall win rate
50%
+ Follow
#3
Paul Choi
Goldman Sachs · Rank #110
Buy
$75.00+98.7% to target
Overall win rate
52%
+ Follow
#4
Serge Belanger
Needham · Rank #129
Buy
$60.00+58.9% to target
Overall win rate
46%
+ Follow
#5
Jason Gerberry
B of A Securities · Rank #160
Buy
$77.00+104.0% to target
Overall win rate
47%
+ Follow
XENE stock forecast FAQ
What is XENE's average 12-month price target?+
The 10 active firms with a live target average $67.40 for Xenon Pharmaceuticals Inc over the next 12 months, ranging from a $90.00 high to a $46.00 low, as of Nov 19, 2026.
Is XENE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for XENE?+
The Street-high target is $90.00 (Baird), and the Street-low is $46.00 (Deutsche Bank). The average of all 10 active-firm targets is $67.40.
How many active Wall Street firms cover XENE?+
10 active firms have a recognized rating on Xenon Pharmaceuticals Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering XENE?+
Among analysts who currently cover XENE, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $55.00 target.
What is Xenon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.21 per share (range $-1.30 – $-1.02) across 5 analysts. Full-year EPS is projected at $-4.56, rising to $-4.67 the following year.
How much revenue is Xenon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $1.4M, growing to $30.0M next year.
Have analysts been upgrading or downgrading XENE lately?+
As of Nov 19, 2026, 9 of 10 active firms rate XENE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XENE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.